A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/ Placebo After Combination Chemotherapy for Patients With Advanced or Recurrent Endometrial Cancer
Phase of Trial: Phase II/III
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Selinexor (Primary)
- Indications Carcinoma; Endometrial cancer
- Focus Therapeutic Use
- Acronyms SIENDO; SIENDO / ENGOT-EN5
- Sponsors Karyopharm Therapeutics
- 19 Sep 2019 Planned End Date changed from 1 Jan 2021 to 1 Mar 2023.
- 19 Sep 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Mar 2023.
- 09 May 2019 According to a Karyopharm media release, enrollment completetion for this study is expected in 2020.